# Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels

> **NCT01678313** · PHASE2 · COMPLETED · sponsor: **Buddhist Tzu Chi General Hospital** · enrollment: 140 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)
- **DRUG:** Doxazosin 4 mg every day (QD)

## Key facts

- **NCT ID:** NCT01678313
- **Lead sponsor:** Buddhist Tzu Chi General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2014-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01678313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01678313, "Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01678313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*